Dr. Garland is a 35 year veteran of pharmaceutical discovery and development. Previously, Dr. Garland served as VP of Development at Lpath Therapeutics and VP of Scientific Affairs at Atairgin Technologies Inc., He served for 20 years at Roche, where he was Head of International Project Management. Dr. Garland received a BS in chemistry from the University of San Francisco and a Ph.D. in medicinal chemistry from the University of Washington.

Dr. Yanofsky is a cell biologist, pharmacologist, and project manager with more than 20 years’ experience in the pharmaceutical industry. Previously, he held positions of increasing responsibility in research with Affymax, Receptron, Multispan, and Amunix. At Affymax, he directed the high throughput screening group. He holds a Ph.D. in biochemistry from UC San Francisco, where he served as a post-doctoral student in Herbert Boyer’s laboratory.

Mr. Frenzel is a life science entrepreneur and investor. His previous experience includes co-founding and serving as the CEO or COO of four biomedical companies that achieved an exit for investors, either through IPO or acquisition. Previously, he was director of corporate planning for Syntex, a management consultant with Booz, Allen and the Boston Consulting Group, and an officer in the US Navy. He holds a BS in physics and an MBA from Stanford.